Single-cell RNA sequencing analysis reveals a lack of CXCL13+ T cell subsets associated with the recurrence of cervical squamous cell carcinoma following concurrent chemoradiotherapy
Abstract Concurrent chemoradiotherapy (CCRT) is the standard treatment for advanced cervical cancer, but tumor recurrence within 3–5 years remains a significant challenge. In this study, using 10 × single-cell sequencing, we constructed a cellular atlas of the tumor microenvironment from six CSCC pa...
Saved in:
| Main Authors: | Xia Li, Yanmei Cheng, Mei Ji, Junqi Liu, Zhao Zhao, Qitai Zhao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-06-01
|
| Series: | Cancer Immunology, Immunotherapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00262-025-04083-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: a multicenter, randomized, parallel-controlled, phase II clinical trial
by: Ke Zhang, et al.
Published: (2025-02-01) -
Simultaneous concurrent chemoradiotherapy and esophagectomy for synchronous head and neck and esophageal squamous cell carcinoma: a retrospective review
by: Yu-Ming Huang, et al.
Published: (2025-07-01) -
Retrospective study on the correlation between CXCL13, immune infiltration, and tertiary lymphoid structures in cutaneous squamous cell carcinoma
by: Yulu Chen, et al.
Published: (2025-05-01) -
Immunotherapy concurrently administered with chemoradiotherapy in limited-stage small-cell lung cancer
by: Liuhua Long, et al.
Published: (2025-07-01) -
Nomogram based on the advanced lung cancer inflammation index and other relevant clinical factors for patients with cervical squamous cell carcinoma undergoing concurrent chemoradiotherapy
by: Xiao-Chun Wang, et al.
Published: (2025-07-01)